Adicet Bio: A Deep Value Play Trading Below Cash Value

Friday’s trading session brought a significant surge for Adicet Bio, with its shares climbing 7.85% to close at $0.6482. While the immediate catalyst appeared to be the approval of a new employee stock option plan, the underlying investment thesis reveals a more compelling story: this biotechnology firm is currently valued at less than the cash it holds on its balance sheet, presenting a potential opportunity for value-focused investors.

The most striking aspect of Adicet Bio’s current valuation emerges from examining its financial position. The company’s market capitalization stands at approximately $99.3 million, which appears significantly undervalued relative to its liquid assets.

As of the end of September 2025, Adicet reported Read more...